|

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

RECRUITINGSponsored by University of Roma La Sapienza
Actively Recruiting
SponsorUniversity of Roma La Sapienza
Started2020-09-14
Est. completion2025-09-14
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04464122

Summary

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
* Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).

Exclusion Criteria:

* Severe chronic kidney disease (stage 4-5);
* Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
* Other non-neuroendocrine malignancies.

Conditions6

CancerNeuroendocrine CarcinomaNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumors

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.